The administration of cannabidiol (CBD), a nonpsychotropic cannabinoid, is associated with improved quality of life in patients with Parkinson’s disease, according clinical trial data published online ahead of print in the Journal of Psychopharmacology. Authors reported that the administration of 300 mg doses of CBD per day was associated with “significantly different mean total scores” in subjects’ well-being and quality of life compared to placebo.
I’m playing the piano this week for a production of Noël Coward’s high-farce-comedy-of-manners Hay Fever at Illinois State University, and having a delightful time. Pre-show, intermission, and a few things directly involved in the show, playing music from the 1910′s and 1920′s. Kept me a bit busy.
I did get a chance to see […]